Transgene to Present Data at 2004 ASCO Annual Meeting STRASBOURG, France, May 12 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced the scheduled presentations of data on two product candidates at the American Society of Clinical Oncology annual meeting, June 5-8, 2004 in New Orleans, Louisiana. Mirjana Urozevic, MD, from the Department of Dermatology, University Hospital, Zurich, Switzerland, will present interim results of Transgene's Ad-IFN gamma product candidate currently in a Phase I/II clinical trial in primary cutaneous lymphoma. The Ad-IFN gamma abstract has been selected to receive a 2004 ASCO Foundation Merit Award. Patrick Squiban, MD, Vice-President Medical and Regulatory Affairs of Transgene will present interim results on the MVA-Muc1-IL2 cancer vaccine currently in Phase II clinical trial for lung, prostate and kidney cancer. Presentations: Title: "Phase I/II study of adenovirus-interferon gamma (TG 1042) in primary cutaneous lymphomas (CL)" Date and time of the session: June 6, 2004 - 11:00 am to 12:00 pm --------------------- Title: "MVA-Muc1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim Phase II Data" Date and time of the session: June 7, 2004 - 8:00 am to 12:00 pm About Transgene Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines, immunotherapy products, and delivery technologies for the treatment of diseases for which there is no cure or adequate treatment at present, with a focus on the treatment of cancer. Transgene has five products in clinical development, two of which are in Phase II clinical trials, two in Phase I/II and one that has completed Phase I clinical trial. Transgene's proprietary vector technology platform consists of adenovirus and poxvirus. DATASOURCE: Transgene CONTACT: Patrick Squiban, MD, VP Medical & Regulatory Affairs of Transgene, +33-3-88-27-91-73; Michael Long of Cohn & Wolfe, +1-212-798-9775; Estelle Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn, +33-1-53-70-74-64, both of Image 7, all for Transgene

Copyright